Peptonic Medical

The reason is that the Company needs additional time to complete the report, taking into account the ongoing corporate restructuring. Peptonic is working purposefully to strengthen the company's financial position. The interim report will provide an update on developments during the period, including progress in the restructuring and measures implemented to create a long-term sustainable and profitable business. The company is also postponing the Annual General Meeting and Annual report for the same reason. The new date for the Annual General Meeting will be June 26, 2025 and the Annual report will be published no later than June 5, 2025.

For more information contact:

Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07

About PEPTONIC medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.